CASE STUDY

From IPO to Acquisition: How BPM Guided a Life Sciences Company Through Every Stage of Growth 

July 13, 2026

Services: IPO Readiness Services Industries: Life Sciences

---

A clinical-stage biopharmaceutical company focused on developing treatments for advanced liver disease had a bold vision, and the science to back it up. But navigating the complexities of going public, managing the tax obligations of a newly minted reporting company, and ultimately positioning for a multibillion-dollar acquisition required more than internal resources could provide. That’s where BPM came in.

The Problem 

When the company’s CFO (a former BPM client contact from another engagement) joined the organization ahead of its IPO, he knew exactly who to call. The company was about to make the leap to public markets, and with that came a steep learning curve. As a lean, largely virtual operation, it had limited infrastructure for the rigorous demands of public company compliance: quarterly income tax provisions, expanded disclosure requirements, accelerated 10-K timelines, and SOX 404 compliance. 

Beyond the structural challenges of going public, the company faced technical tax complexity that could have undermined its long-term value. As a publicly traded company, it was now susceptible to Section 382 ownership change limitations, meaning that poorly timed equity raises could have restricted its ability to use valuable net operating losses and tax credits. The company also needed to maximize every available tax advantage as it continued to invest heavily in research and development.

The Solution

BPM became a trusted partner across multiple disciplines, growing the engagement well beyond initial tax compliance work. Key elements of BPM’s support included: 

• IPO readiness and ongoing public company compliance. BPM helped the company stand up the processes and controls needed to meet its new tax reporting obligations, from quarterly income tax provisions, expanded annual 10-K disclosures, and SOX 404 requirements. 
• Section 382 planning. BPM advised the company on how to structure equity raises to avoid triggering ownership changes that could have limited its ability to utilize NOLs and other tax assets, preserving significant future value. 
• R&D tax credits. Because the company was incorporated in 2017, BPM was able to identify and claim refundable R&D tax credits during its first five qualifying years, generating meaningful cash flow (up to $500,000 annually) during a capital-intensive phase of development. 
• Strategic advisory support. Beyond compliance, BPM served as a sounding board on treasury matters, entity structure, and intercompany cash management, helping the company make informed decisions as it scaled. 

The Outcome 

Years of disciplined growth culminated in a landmark exit: the company was acquired by a major global pharmaceutical corporation in a deal valued at over $5 billion. BPM supported the company through the due diligence process, helping to ensure there were no unresolved tax exposures that could complicate or derail the transaction. 

The relationship didn’t end at close. As employees navigated the financial implications of the acquisition, including cash consideration and contingent value rights, BPM Partner Edmond Zhou delivered a presentation walking the company’s workforce through how to properly report their proceeds. BPM Wealth Management Director Mike Watson followed with guidance on planning strategies for the newly liquid employees: charitable foundations, trust structures, and other tools for managing a significant windfall. Several employees, including leadership, went on to engage BPM’s wealth management team for ongoing personal financial planning. 

Ready to Build on the Right Foundation? 

Whether you’re preparing for an IPO, navigating public company compliance, or positioning for an exit, BPM offers the full range of tax, advisory, and wealth management capabilities to support you at every stage.